Analyst Price Target is $30.98
▲ +2.57% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Itamar Medical in the last 3 months. The average price target is $30.98, with a high forecast of $33.85 and a low forecast of $29.00. The average price target represents a 2.57% upside from the last price of $30.20.
Current Consensus is
The current consensus among 6 contributing investment analysts is to hold stock in Itamar Medical. This Hold consensus rating has held steady for over two years.
Itamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. It develops and markets two products, namely, WatchPAT and EndoPAT. The WatchPAT diagnoses sleep apnea, which has been proven to be a substantial risk factor in cardiac disease. The EndoPAT diagnoses endothelial malfunction, which is a proven predictor of cardiovascular disease. The company was founded by Yaron Giora , Martin Gerstel, Peretz Lavie, and Daniel Gur on January 15, 1997 and is headquartered in Caesarea, Israel.